SOURCE: NuGene International, Inc.

NuGene International, Inc.

June 29, 2015 07:05 ET

One of the World's Largest Dermatologist-Owned E-Commerce Sites to Feature NuGene Kathy Ireland as a Premier Product Line

NuGene International, Inc. Expands Distribution and Consumer Awareness With Selection by

IRVINE, CA--(Marketwired - Jun 29, 2015) - NuGene International, Inc. ("NuGene") (OTCQB: NUGN), a developer, manufacturer and marketer of advanced skin and hair care lines utilizing adipose derived human stem cells and stem cell media, has announced that (one of the largest and best recognized prestige brand websites) has selected NuGene Kathy Ireland's products as a premier line of business for its prestige branded e-commerce store. is a premier dermatologist-owned and operated beauty website serving hundreds of thousands of customers. Under the direction of award-winning board-certified dermatologist and cosmetic surgeon, Joel Schlessinger M.D., LovelySkin is an exclusive cosmeceutical store that has been featured in multiple publications including Women's Wear Daily. The website offers professional-grade skin care formulas as well as spa-quality and salon-quality products.

"I am delighted to carry NuGene as I have followed their products intently for some time now. The concept of adipose stem cells leading to regeneration of collagen and other fibroblasts has intrigued me for years. NuGene's formulation eliminates much of the risk found in other growth factor products while leading to a renewal of our skins' natural innate resources. Use of these products is a simple way to rejuvenate our skin in combination with other actives such as antioxidants. Moreover, the team at NuGene is phenomenal. I am truly honored to be a part of their family," stated Dr. Schlessinger when announcing the inclusion of the NuGene product line into his top rated portal.

Joel Schlessinger M.D. is the editor-in-chief, Cosmetic Surgery, for Practical Dermatology and the founder of Cosmetic Surgery Forum, a multi-specialty educational symposium that covers the latest research, treatment and techniques in dermatology and cosmetic surgery. Dr. Schlessinger has been consistently voted the best cosmetic surgeon and dermatologist in Omaha, Nebraska (now 16 years in a row the winner of the best cosmetic surgeon in Omaha and best dermatologist) and one of America's Top Docs, US News Best Doctors and Best Doctors in America (both dermatology and pediatric dermatology) as well as an Elle Beauty Genius award winner.

In addition to an interest in cosmeceuticals and cosmetic surgery, Dr. Schlessinger operates a clinical trials unit (Advanced Skin Research Center), which reports having performed over 300 trials in 22 years, including trials of Dysport, Evolus and Xeomin (new forms of botulinum toxin), trials of Kybella, Liposonix, Revance topical botulinum toxin and over 10 new compounds for psoriasis.

"We are excited to have our NuGene Skincare products available at, one of the nation's leading skincare destinations. We believe our NuGene products are revolutionary as NuGene is unlike anything else on the market today. Aging, sun damage, lines and wrinkles are beautifully addressed by our collection. We thank for joining us in offering the greatest innovation in skincare to you," said Kathy Ireland, Chair, CEO and Chief Designer for Kathy Ireland Worldwide.

"We are honored and excited by Dr. Schlessinger's selection of our product line," said Fady Elias M.D., NuGene's Director of Professional Business Development. "His endorsement of our products further advances our emerging leadership in this growing industry."

About NuGene International, Inc.

NuGene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media. The US Department of Health and Human Services calls regenerative medicine the "next evolution of medical treatments." The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report. NuGene's cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue. NuGene's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations. NuGene's goal is to leverage its knowledge and expertise to develop age defying cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

Forward-Looking Statements

This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene International may not proceed as contemplated, and by all other matters and assumptions specified in NuGene's filings with the Securities and Exchange Commission, especially those risks and other matters described under "Risk Factors" within NuGene's Form 10-Q filed with the Commission on May 15, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information.

Contact Information

  • Investor/ Media Relations:
    Jay Goth